Cantor Fitzgerald Predicts UTHR FY2026 Earnings

United Therapeutics Co. (NASDAQ:UTHR - Free Report) - Cantor Fitzgerald issued their FY2026 EPS estimates for shares of United Therapeutics in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer expects that the biotechnology company will earn $29.26 per share for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $405.00 target price on the stock. The consensus estimate for United Therapeutics' current full-year earnings is $24.48 per share.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. During the same quarter in the previous year, the business earned $6.17 earnings per share. The business's revenue was up 17.2% compared to the same quarter last year.

Several other brokerages also recently issued reports on UTHR. JPMorgan Chase & Co. cut their price target on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating for the company in a report on Thursday, May 1st. Morgan Stanley raised their target price on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research note on Thursday, May 1st. Wells Fargo & Company reiterated an "equal weight" rating and issued a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. Wall Street Zen downgraded shares of United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 2nd. Finally, Bank of America reduced their price objective on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a report on Wednesday. Four analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $393.08.

United Therapeutics Stock Down 1.0%

Shares of UTHR stock traded down $2.79 during trading on Tuesday, reaching $283.35. 564,424 shares of the company's stock were exchanged, compared to its average volume of 452,608. United Therapeutics has a twelve month low of $266.98 and a twelve month high of $417.82. The firm's fifty day moving average price is $300.50 and its 200-day moving average price is $330.86. The stock has a market capitalization of $12.78 billion, a PE ratio of 12.44, a PEG ratio of 0.97 and a beta of 0.57.

Insider Transactions at United Therapeutics

In other United Therapeutics news, Director Tommy G. Thompson sold 2,500 shares of the stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $318.80, for a total transaction of $797,000.00. Following the sale, the director now directly owns 8,480 shares in the company, valued at $2,703,424. This represents a 22.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the firm's stock in a transaction dated Thursday, April 17th. The shares were sold at an average price of $283.78, for a total transaction of $3,121,580.00. Following the completion of the transaction, the executive vice president now directly owns 36,781 shares in the company, valued at approximately $10,437,712.18. This represents a 23.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 68,500 shares of company stock valued at $20,828,390. 10.30% of the stock is currently owned by company insiders.

Institutional Trading of United Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in UTHR. Newbridge Financial Services Group Inc. acquired a new position in United Therapeutics during the fourth quarter valued at approximately $25,000. SVB Wealth LLC bought a new position in shares of United Therapeutics in the 1st quarter valued at $32,000. Dunhill Financial LLC raised its holdings in shares of United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after buying an additional 50 shares in the last quarter. Geneos Wealth Management Inc. raised its holdings in shares of United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock worth $45,000 after buying an additional 85 shares in the last quarter. Finally, Sound Income Strategies LLC bought a new stake in shares of United Therapeutics during the 1st quarter worth $49,000. Institutional investors own 94.08% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.